Concerns have been raised regarding the safety of angiotensin converting enzyme
inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in patients with coronavirus …

Many countries have been affected by the worldwide outbreak of COVID‐19. Among
Western countries, Italy has been particularly hit at the beginning of the pandemic …

Angiotensin-converting enzyme 2 (ACE2) is an aminopeptidase that converts Angiotensin
(Ang) II into Ang (1-7). Coronavirus uses ACE2 as a cellular receptor to invade target cells …

The recent emergence of coronavirus disease-2019 (COVID-19) as a global pandemic has
prompted scientists to address an urgent need for defining mechanisms of disease …

Background Circulatory shock is a common syndrome with a high mortality and limited
therapeutic options. Despite its discovery and use in clinical and experimental settings more …

Since December 2019, the coronavirus 2019 (COVID-19) pandemic has rapidly spread and
overwhelmed healthcare systems worldwide, urging physicians to understand how to …

Objective To review evidence on routinely prescribed drugs in the UK that could upregulate
or downregulate ACE2 and potentially affect COVID-19 disease. Design Systematic review …

Angiotensin II (Ang II), part of the renin–angiotensin–aldosterone system (RAS), is a potent
vasoconstrictor and has been recently approved for use by the US Food and Drug …

Coronary heart diseases are of high relevance for health care systems in developed
countries regarding patient numbers and costs. Disappointingly, the enormous effort put into …

Acute pulmonary embolism (APE) with cardiac arrest (CA) is associated with a high mortality
rate. Even upon return of the spontaneous circulation (ROSC), APE‑CA survivors are prone …